Is star coronavirus stock Moderna (NASDAQ: MRNA) beginning a new phase of its late-pandemic life? This might have been a concern of investors after the company announced Wednesday morning that David Meline, who has served as CFO since nearly the start of the pandemic, is stepping down from the company. After all, Meline guided Moderna to a series of impressive quarterly beats on the back of the successful coronavirus vaccine the company developed and brought to market.
Vaccines, treatments and tests will soon all be commercially available. But what that means for consumers' out-of-pocket costs is unclear.
Regulatory and pipeline updates from Gilead (GILD) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.